GSK Signs Agreement with the WHO to Donate 50 Million Doses of Pandemic H1N1 Vaccine for Distribution to Developing Countries

Tue, 11/10/2009 - 3:24am
GlaxoSmithKline (GSK) today announced that it has signed an agreement with the World Health Organization (WHO) to donate 50 million doses of its adjuvanted pandemic H1N1 influenza vaccine to WHO for distribution to developing countries most in need. GSK is working with WHO and health authorities to prepare for initial shipments of the vaccine to developing countries by the end of November. “GSK is committed to supporting governments and health authorities around the world in their efforts to protect their populations against this pandemic. Our commitment recognises the needs of developing countries, and this donation of 50 million doses will enable vaccination to begin soon in some of the world’s poorest countries.” said Andrew Witty, CEO, GlaxoSmithKline. In addition to the donation made to WHO, in order to further ensure that developing countries have access to pandemic vaccines, GSK is also supplying its vaccine to developing countries under a tiered pricing policy, based on World Bank Classification and GAVI eligibility. GAVI–eligible countries, which include the world’s poorest, would receive highly preferential prices, based on volume orders. GSK has allocated 20% of overall production of its Canadian manufacturing site to developing countries. The donation to WHO is part of this allocation. "We welcome this very generous donation by GlaxoSmithKline, which will go to protect the health of the world's poorest people. This is a real gesture of global solidarity towards those who would not be otherwise able to have access to the vaccine," said Dr. Margaret Chan, Director–General, WHO. "WHO will now work to see that these vaccines are distributed to those who need them." In addition to this agreement on vaccines, GSK continues to have discussions with WHO about a donation of its antiviral medicine, Relenza. A tiered-pricing policy based on World Bank classification of countries is also in effect for this antiviral medicine, and the company is making Relenza Rotacaps and Diskhaler available at not-for-profit prices to the world’s 50 least developed countries.

Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.